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Interleukin-29 modulates proinflammatory
cytokine production in synovial inflammation of
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Abstract
Introduction: The immunoregulatory function of interleukin (IL)-29 has recently been recognized. However, little is
known about the involvement of IL-29 in the pathogenesis of rheumatoid arthritis (RA). This study aimed to
examine the expression profiles of IL-29 in blood, synovial fluid (SF) and synovium in RA patients and investigate
the effect of IL-29 on cytokines production in RA synovial fibroblasts.
Methods: The transcript levels of IL-29 and its specific receptor IL-28Ra in peripheral blood mononuclear cells
(PBMC) and synovium were determined by real-time reverse transcription-polymerase chain reaction (real-time
PCR). The concentrations of IL-29 in serum and synovial fluid (SF) were quantified by enzyme-linked immunoassay
(ELISA), and the correlation of serum IL-29 levels with disease activity in RA patients was investigated. Furthermore,
the expression of IL-29 in RA synovium was examined by immunohistochemistry and double immunofluorescence
analysis. Finally, the expression of IL-6, IL-8, IL-10, IL-17 and matrix metalloproteinase-3 (MMP-3) in synovial
fibroblasts upon IL-29 stimulation was determined by real-time PCR.
Results: IL-29 and IL-28Ra mRNA expression in PBMC was significantly increased in patients with RA compared
with healthy controls (HC). The serum levels of circulating IL-29 were higher in RA than those in HC. Increased
IL-29 levels were detected in RA SF when compared with osteoarthritis (OA) SF. However, serum IL-29 levels
showed no significant correlation with RA disease activity. IL-29 was mostly expressed in the lining region of RA
synovium. Moreover, IL-29 was expressed predominately in synovial macrophages and fibroblasts. RA synovial
fibroblasts exposed to IL-29 specifically upregulated IL-6, -8 and MMP-3 but downregulated IL-10.
Conclusions: The findings in the present study indicate, for the first time, that IL-29 is dysregulated in patients
with RA, which may contribute to the RA pathogenesis via inducing the production of proinflammatory cytokines,
chemokines or matrix metalloproteinases in synovial fibroblasts.
Introduction
Rheumatoid arthritis (RA) is characterized by chronic
inflammation, articular destruction and abnormal
immune response. Although the pathogenesis of RA
remains unclear, the accumulated evidence has sug-
gested that cytokines play an important role in the
development and maintenance of RA disease activity. In
the past decade, numerous studies have shown that a
variety of cytokines including TNF-a, IL-1a, -1b, -6, -7,
-15, -17, -18, -21, -23, -32, and -33 contribute to RA
pathogenesis [1]. Consequently, biologics that target
TNF-a or IL-6 for the treatment of RA have been
extensively studied and have profoundly changed RA
treatment strategy. Considering about 30% of RA
patients could experience an inadequate response to
current biologics, it is still a challenge to identify key
cytokines involved in RA. Recently, the upregulation of
interferon-inducible genes has been found in the syno-
vial lining regions and whole blood of patients with RA,
suggesting that interferons (IFNs) may also play an
important role in the pathogenesis of RA [2,3].
The classical interferon (IFN) family cytokines are
known to be critically involved in both innate and
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adaptive immune responses during viral infection and
autoimmune inflammation. The IFN family includes
three subfamilies (type I, type II and type III). Type I
IFNs include IFN-a, b, ω, , ε, τ, ζ, δ and ν subtypes [4],
whereas type II IFNs are represented by IFN-g. Type III
IFNs consist of three newly identified members, IL-29
(IFN-l1), IL-28A (IFN-l2) and IL-28B (IFN-l3) [3,5].
Type III IFNs closely resemble the type I IFNs in terms
of expression after virus infection as well as intracellular
signaling and activation of antiviral host factors in sus-
ceptible cells [6]. However, the striking differences
between type I and III IFNs include the cell-type and
tissue-specific distribution of their respective receptor
complexes [7]. Type I IFNs signal through a universally
expressed cell surface receptor complex composed of
two subunits, IFNAR1 and IFNAR2 [8]. By contrast,
type III IFNs act through a cell surface receptor com-
posed of a unique IL-28 receptor a chain (IL-28Ra, also
known as IFNLR1) and IL-10R2 chain that is also the
subunit of the receptor of IL-10, IL-22 and IL-26 [9].
The specific activity of type III IFNs is determined in
part by the expression level of its receptor chain IL-
28Ra, which is expressed on a limited range of tissues
and cell types, such as lung, heart, liver and prostate tis-
sues, dendritic cells, A549 and HeLa S3 cell lines
[7,10,11]. Recent studies have revealed the unique biolo-
gical activities of type III IFNs in and beyond innate
antiviral immunity [12,13]
IL-29 shows the highest level of activity among three
members of type III IFNs and has exhibited its potential
immunoregulatory function. Recent studies have reported
that IL-29 acts an inhibitor of human Th2 responses and
modulates the Th1/Th2 response by the diminution of
IL-13 secretion in vitro [14,15]. It has been shown that
IL-29 specifically upregulates the levels of IL-6, IL-8 and
IL-10 secreted by monocytes [16] and also enhances IL-2-
dependent proliferation of CD4+CD25+Foxp3+ T cells
induced by dendritic cells [17]. Interestingly, a recent
study has reported that IL-29 plays an important role in
the pathogenesis of systemic lupus erythematosus (SLE)
by inducing the secretion of chemokines IP-10, MIG and
IL-8 in peripheral blood mononuclear cells [18,19].
Although accumulated data have indicated a crucial role
of IL-29 in modulating immune response and enhancing
inflammatory reaction, whether IL-29 is involved in the
pathogenesis of RA remains unclear.
In this study, we investigated whether the expression of
IL-29 is dysregulated in patients with RA. We found sig-
nificantly elevated levels of IL-29 in peripheral blood
mononuclear cells (PBMC), serum and synovial fluid (SF)
of RA patients compared with healthy controls or
osteoarthritis (OA) patients. Moreover, we identified
both synovial macrophages and fibroblasts as the major
cellular source for IL-29 expression in RA synovial tissue.
Furthermore, our in vitro studies revealed that recombi-
nant IL-29 can stimulate MH7A cells, a human synovial
fibroblast cell line, for enhanced production of proin-
flammatory cytokines, indicating a novel function of IL-
29 in driving synovial inflammation during RA develop-
ment. Our results further support the hypothesis that IL-




Human IL-29 ELISA reagent kits were purchased from
Adlitteram Diagnostic Laboratories (San Diego, CA, USA).
Rabbit anti-human IL-29/IL-28Ra polyclonal antibody,
and mouse anti-human CD68 monoclonal antibody were
purchased from Abcam (Cambridge, MA, USA), mouse
anti-human fibroblast growth factor-basic (FGF-2) mono-
clonal antibody from Millipore (Billerica, MA, USA),
recombinant human IL-29 and TNF-a were from Pepro-
tech (Rocky Hill, NJ, USA). Donkey anti-rabbit IgG-R and
goat anti-rabbit IgG/TRITC were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). DyLight™488-
conjugated AffiniPure donkey anti-mouse IgG, peroxi-
dase-conjugated sheep anti-rabbit secondary antibody and
peroxidase-conjugated sheep anti-mouse secondary anti-
body were from Jackson Immunoresearch (West Grove,
PA, USA). The Diaminobenzidine (DAB) substrate kit was
from Dako (Glostrup, Denmark). PrimeScript™ RT Mas-
ter Mix and SYBR Green PCR Master Mix were obtained
from Takara Biotechnology (Dalian, China). Dulbecco’s
modified Eagle’s medium (DMEM) was from Gibco
(Carlsbad, CA, USA) and fetal bovine serum (FBS) from
Biosource International (Camarillo, CA, USA).
Patients and samples
Patients with RA, OA and healthy control (HC) patients
were recruited randomly from the First Affiliated Hospi-
tal of Nanjing Medical University. Blood samples were
collected from 54 RA patients and 60 HC. SF samples
were obtained from 20 RA and 20 OA patients. Syno-
vium samples were obtained from six RA patients and
five HC after therapeutic synovectomy or amputation.
The classification of RA fulfilled the American College
of Rheumatology (ACR)/European League Against
Rheumatism (EULAR) 2009 diagnostic criteria [20]. The
general characteristics of both patients and controls sub-
jects are summarized in Table 1. All patients were
recruited from the baseline and had not yet been treated
with disease-modifying anti-rheumatic drugs (DMARDs)
and/or steroids before their blood samples were col-
lected. This study was approved by the Ethical Commit-
tee of the First Affiliated Hospital of Nanjing Medical
University, and all donors provided written informed
consent.
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Blood samples were collected from peripheral veins.
PBMCs were isolated by Ficoll-Hypaque density centri-
fugation. Serum and SF samples were stored at -80ºC.
Synovial biopsies were stored in liquid nitrogen for
mRNA analysis or in Carnoy’s fixative for histological
analysis.
Real-time PCR
Total RNA was extracted from PBMC, synovial tissue
and fibroblasts using TRIzol (Invitrogen, Carlsbad, CA,
USA). Reverse transcription reaction was conducted at
37ºC for 15 min, 85ºC for 5 sec in a 20 μL mixture con-
taining 1 μg of total RNA, and PrimeScript™ RT Master
Mix. Each real-time PCR was prepared in a 20 μL reac-
tion mixture containing 10 μL SYBR Green PCR Master
Mix, 1 μL cDNA, 0.8 μL primers (200 nM each of for-
ward and reverse primers), and conducted on a ABI
Prism 7900 sequence detector (Applied Biosystems,
Carlsbad, CA, USA). Cycling conditions consisted of
initial denaturation 30 sec at 95ºC, followed by 40 cycles
of 5 sec at 95ºC, and 30 sec at 60ºC. The primer
sequences are summarized in Table 2. All samples of
RA and controls were assayed in triplicate. Relative gene
expression was determined by the 2-ΔΔct method.
ELISA
Levels of IL-29 in serum and SF were measured by
ELISA according to the manufacturer’s instructions. The
correlation was analyzed between IL-29 and laboratory
values, including erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), anti-cyclic citrullinated pep-
tides (CCP) and rheumatoid factor (RF) in serum of RA
patients.
Immunohistochemical analysis
Specimens were fixed in Carnoy’s fixative and embedded
in paraffin wax. Paraffinized synovial tissues were sec-
tioned to 3μm thickness, deparaffinized in xylene and
rehydrated through a series of concentrations of ethanol.
After inactivation of endogenous peroxidase, sections
were blocked by incubation with 5% bovine serum album
for 30 min at room temperature, then incubated with
rabbit anti-human IL-29 antibody at 4ºC overnight in a
humidified chamber. After washing, sections were next
incubated with peroxidase-conjugated goat anti-rabbit
secondary antibody for 1 h at room temperature. The
reactions were developed using a DAB substrate kit, with
hematoxylin as counterstain. Each slide was evaluated by
one of the authors (Ms. Xiaoke Feng) under a microscope
Table 1 Clinical and laboratory characteristics in patients with rheumatoid arthritis (RA) and osteoarthritis (OA), and
healthy control (HC) subjects.
Parameter RA (n = 54) OA (n = 20) HC (n = 60)
Age (y) 48.2 (17-65) 61 (57-82) 43.4 (24-64)
Sex (female/male) 34/6 24/4 20/5
Median age at onset (y) 40 (13-63) - -
Median disease duration (m) 36 (3-444) - -
Number of tender joints 6.50 (0-28) - -
Number of swollen joints 1.50 (0-28) - -
ESR (mm/h) 37.5 (10-125) - -
CRP (mg/l) 10.32 (2.97-84.5) - -
RF (U/I) 76.4 (10.3-954) - -
DAS28-ESR 4.58 ± 2.08 - -
BMI (kg/m2) 22.45 (16.65-28.55) - 22.91 (17.33-26.17)
Total cholesterol (mmol/l) 4.41 (2.55-6.16) - 5.19 (3.9-7.1)
Triglycerides (mmol/l) 1.44 (0.49-2.15) - 1.46 (0.84-3.11)
The values shown represent the median and the ranges. BMI, body mass index; CRP C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte
sedimentation rate; RF, rheumatoid factor.
Table 2 List of the sequence of gene primers.
Gene name Forward (5’ to 3’) Reverse (5’ to 3’)
Human IL-29 GAAGCAGTTGCGATTTAGCC GAAGCTCGCTAGCTCCTGTG
Human IL-28Ra CCTCCCCAGAATGTGACGC GGAGCCATGTCAGGTACACG
Human IL-6 AACCTGAACCTTCCAAAGATGG TCTGGCTTGTTCCTCACTACT
Human IL-8 CATACTCCAAACCTTTCCACCCC TCAGCCCTCTTCAAAAACTTCTCCA
Human IL-10 CAAATGAAGGATCAGCTGGACAA GCATCACCTCCTCCAGGTAAAAC
Human IL-17 CCCGGACTGTGATGGTCAAC GCACTTTGCCTCCCAGATCA
Human MMP-3 CAGGCTTTCCCAAGCAAATA TTGCATTTGGGTCAAACTCC
Human GAPDH AGAAGGCTGGGGCTCATTTG AGGGGCCATCCACAGTCTTC
Wang et al. Arthritis Research & Therapy 2012, 14:R228
http://arthritis-research.com/content/14/5/R228
Page 3 of 10
(Nikon, Tokyo, Japan). Tissue sections were scored for
staining of the lining on a 0 to 5 scale [21] as follows: 0 =
no staining, 1 = few of the cells positively stained, 2 =
some (fewer than half) of the cells stained, 3 = approxi-
mately half of the cells stained, 4 = more than half of the
cells stained, and 5 = all cells stained. For each section,
the number of positively stained cells was counted in 20
fields.
For double immunofluorescence labeling, tissue sections
were incubated with a mixture of primary antibodies (rab-
bit anti-IL-29 pAb, mouse anti-CD68 or FGF-2 mAb) at 4
ºC overnight. Slides were next reacted with a mixture of
donkey anti-rabbit IgG-R, DyLight™488-conjugated don-
key anti-mouse IgG, and 40, 6-diamidine-20-phenylindole
dihydrochloride (DAPI) for 1 h. Images were acquired and
processed digitally under a fluorescence microscope
(Nikon, Tokyo, Japan).
Cell lines and treatment
MH7A was a generous gift from Dr. David Yu (UCLA,
USA), which was isolated from intra-articular soft tis-
sues of the knee joints of RA patients and established by
transfection with the SV40 T antigen [22]. Cells were
cultured in DMEM supplemented with 10% FBS, peni-
cillin and streptomycin in a humidified atmosphere of
5% CO2 at 37ºC.
Cells were exposed to recombinant human IL-29 (rIL-
29) at various concentrations (1, 10 and 100 ng/ml) or
TNF-a (10 ng/ml). At 24 h and 48 h following incubation,
cells were collected for the detection of IL-6, IL-8, IL-10,
IL-17 and matrix metalloproteinase-3 (MMP-3) by real-
time PCR.
Immunofluorescence staining of IL-28Ra in cells
The biological activity of IL-29 was determined in part by
the expression level of its specific receptor chain IL-28Ra.
MH7A cells were washed in PBS twice for 1 min and then
fixed with 4% paraformaldehyde for 15 min. The cells
were incubated with rabbit anti-human IL-28Ra antibody
for 1 h in 37ºC. After incubation, the cells were washed
twice and further incubated with goat anti-rabbit IgG/
TRITC for 1 h in room temperature. Finally, the cells were
washed and incubated with DAPI staining solution for
2 min, and analyzed by fluorescence microscopy (Nikon,
Tokyo, Japan). IL-28Ra was stained red and nuclei were
stained in blue.
Statistical analysis
Statistical analyses were performed with SPSS version 18.0
software (SPSS, Chicago IL, USA). Data were expressed as
mean ± SD. Differences between two groups were per-
formed with Student’s t test for parametric data and
Mann-Whitney U test for nonparametric data. The Pear-
son correlation test was used to evaluate the correlation
between serum IL-29 levels and laboratory values and clin-
ical features. For all experiments, P <0.05 was considered
as significant.
Results
Upregulated expression of IL-29 and its receptor
transcripts in PBMCs from RA patients
To explore whether IL-29 was involved in the pathogen-
esis of RA, we first examined the expression of IL-29
mRNA and its receptor IL-28Ra in PBMC by real-time
PCR. It was found that expression of IL-29 and IL-28Ra
mRNA was significantly higher in RA PBMCs when
compared to HC (P = 0.001 and 0.0442, respectively;
Figure 1A, B).
Increased serum and SF levels of IL-29 in RA patients
To examine the protein level of IL-29 in serum and SF,
we measured the concentrations of IL-29 in the serum of
RA patients and HC and in SF from patients with RA
and OA. Our results showed that serum levels of circu-
lating IL-29 were significantly higher in RA (24.56 ±
15.85 pg/ml) than those in HC (5.62 ± 3.19 pg/ml,
P <0.0001; Figure 2A). Similar to serum samples, the
mean level of IL-29 in SF was increased in RA (16.21 ±
11.12 pg/ml) compared to OA (9.37 ± 4.49 pg/ml) (P =
0.0397) (Figure 2B).
To further evaluate the relationship between circulating
IL-29 levels and disease activity in RA patients, we next
determined the correlations between IL-29 and 28-joint
Disease Activity Score (DAS28) as well as laboratory char-
acteristics including CRP, ESR, RF, and anti-CCP. No sig-
nificant correlation between serum levels of circulating IL-
29 and DAS28, CRP, ESR, RF, and anti-CCP was found
(data not shown). However, when RA patients were
divided into active and inactive groups according to
DAS28 scores (that is, the active groups was defined as a
DAS28 score ≥3.2 based on the EULAR diagnostic criteria
[20]), it was found that active groups conferred moderately
higher IL-29 mRNA and protein levels than inactive
groups albeit without statistical significance.
IL-29 expression in synovial tissue
Next we sought to examine the localization of IL-29
expression in RA synovial tissues and performed immuno-
histochemical analysis on six RA and five normal synovial
tissue samples. As shown in Figure 3A, IL-29 was mainly
expressed in the lining layers of RA synovium. We also
semiquatitatively analyzed protein levels of IL-29 expres-
sion using a scoring system by immunohistochemistry
(Figure 3B), and found that IL-29 expression was signifi-
cantly increased in RA synovium compared to normal
synovium (P = 0.0097).
To further determine which cell type expresses IL-29,
double immunofluorescence staining was performed in
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RA synovium using specific antibodies against CD68
and FGF-2 serving as markers of macrophages and
fibroblasts, respectively (Figure 4). In the lining layers of
the same section used in the above experiments, IL-29-
positive cells were stained in red whereas CD68- or
FGF-2-positive cells were stained in green. In the
merged image, IL-29 positive cells were co-stained with
anti-CD68 or anti-FGF-2 as shown in yellow. We found
that both macrophages and synovial fibroblasts
expressed IL-29, which suggest that these cells might be
the important cellular sources of IL-29 in RA synovium.
Recombinant IL-29-induced cytokine production in
MH7A cells
IL-28Ra (also known as IFNLR1) is the specific receptor
of IL-29. Thus, we first examined the expression of
IL-28Ra in MH7A cells. As shown in Figure 5A,
IL-28Ra was expressed in MH7A cells, implying that
MH7A cells may respond to IL-29 stimulation.
To investigate the potential function of IL-29 in RA, we
examined the cytokine profile produced by RA fibroblast
cell line-MH7A cells upon IL-29 stimulation. MH7A
cells were either untreated or treated with rhIL-29 at
concentrations from 1, 10 and 100 ng/ml for 24 h and 48
h, respectively, and TNF-a (10 ng/ml) was used as a posi-
tive control. Then, cells were harvested for RT-PCR ana-
lysis of IL-6, -8, -10, -17 and MMP-3 expression. As
shown in Figure 5, the expression levels of IL-6, -8 and
MMP-3 were significantly upregulated in MH7A cells
after stimulation with 100 ng/ml rhIL-29 but IL-10
expression was downregulated. Interestingly, IL-17
expression was not changed after 24 h incubation with
Figure 2 Increased expression of IL-29 in rheumatoid arthritis (RA) serum and synovial fluid (SF) compared to in healthy control (HC)
serum and osteoarthritis (OA) SF. Levels of IL-29 in serum (A) from RA (n = 54) and HC (n = 60), and SF (B) from RA (n = 20) and OA (n =
20) were quantified by ELISA. Values are the mean ± SD. Actual P values are shown in the graph.
BA 
Figure 1 Increased expression of IL-29 and IL-28Ra in rheumatoid arthritis (RA) peripheral blood mononuclear cells (PBMC) compared to in
healthy control (HC) PBMC. Levels of mRNA for IL-29 (A) and IL-28Ra (B) in PBMC from RA (n = 40) and HC (n = 40) were determined by real-time
PCR. Relative gene expression was determined by the 2-ΔΔct method. Values are the mean ± SD. Actual P values are shown in the graph.
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rhIL-29 at a dose range of 1 to 100 ng/ml in culture (data
not shown). Notably, rhIL-29 treatment upregulated the
levels of IL-6, IL-8, IL-10 and MMP-3 expression in a
dose-dependant fashion, but not in a time-dependant
fashion after 24 or 48 h incubation (48 h data not
shown).
Discussion
IL-29 is a new member of type III IFN family of cytokines
that has been shown to be involved in immune responses
including inhibition of viral infection and proliferation of
tumor cells [12,23]. However, the role of IL-29 in the
pathogenesis of RA remains unknown. In this study, we
characterized, for the first time, IL-29 expression in
blood and SF of RA patients. We found that mRNA levels
of IL-29 and its specific receptor IL-28Ra in PBMC were
significantly higher in RA than those in HC. Levels of
IL-29 were greatly elevated in RA serum compared with
HC. Moreover, IL-29 levels were significantly higher in
RA SF than that in OA SF. Together, these data suggest
Figure 3 Increased expression of IL-29 in rheumatoid arthritis (RA) synovium compared to healthy control (HC) synovium. RA (n = 6)
and HC (n = 5) synovium were stained with rabbit anti-human IL-29 (A), and immunostaining was scored on a 0 to 5 scale (B). Values in (B) are
the mean ± SD. Actual P values are shown in the graph.
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that IL-29 expression is dysregulated with potentially
enhanced biological function in patients with RA. There-
fore, we further examined the correlation between blood
IL-29 levels and disease activity in RA, together with sev-
eral laboratory values. However, we did not find any sig-
nificant difference of IL-29 level in blood between RA
patients with active and inactive disease, and serum IL-29
protein levels were also not correlated well with DAS28
or CRP, ESR, anti-CCP and RF levels. Given IL-29 has
been shown to induce apoptosis and suppress the cell
proliferation of human CD4+ T cells [24,25], it is possible
that IL-29 may interact with other pathways involved in
RA pathogenesis in addition to inflammation. Alterna-
tively, the lack of a significant association may be attribu-
ted to the modest sample size, the restriction in the
range of the measure of disease activity and the high
standard deviations of CRP and ESR value in our
patients. Hence, further prospective and multicenter stu-
dies with a larger sample size are needed to determine
whether IL-29 can serve as a biomarker for disease activ-
ity for RA patients.
A characteristic feature of RA is the hyperplasia of the
synovial tissue, resulting from the infiltration of various
types of immune cells secreting numerous cytokines, che-
mokines, and matrix metalloproteinases (MMPs) that
promote inflammation and joint destruction through
autocrine and paracrine mechanisms [26]. In particular,
synovial fibroblasts and macrophages have been identi-
fied as the major cell population in the synovial tissue for
overproduction of both proinflammatory cytokines and
MMPs. Therefore, we further examined whether local
IL-29 expression in synovial tissue is dysregulated and
how IL-29 modulates synovial inflammation in RA
patients. Our results showed for the first time that the
number of IL-29-positive cells in RA synovium lining
was substantially higher than that in HC. Notably, we
identified both synovial macrophages and fibroblasts as
the major cellular source for IL-29 expression in RA
synovial tissue.
Furthermore, we investigated the function of IL-29 in
RA synovial fibroblasts in vitro and found that rIL-29
could activate human synovial fibroblasts to produce cyto-
kines IL-6, IL-8 and MMP-3, which may promote inflam-
mation and joint destruction in RA. However, rIL-29
failed to induce IL-17 expression, suggesting little effect of
IL-29 on inducing IL-17 production. Several studies have
demonstrated the ability of IL-29 to regulate cytokine pro-
duction in both peripheral blood mononuclear cells and
dendritic cells upon viral infections or activation via toll-
like receptor-mediated signaling [14,15,25]. Our current
findings have suggested that IL-29 is able to activate RA
synovial fibroblast cells to produce proinflammatory cyto-
kines. However, further studies are needed to determine
whether IL-29 can stimulate cytokine production in pri-
mary synovial fibroblasts from RA patients.
Based on current studies, it is interesting to compare
the role of different types of IFNs in the pathogenesis of
RA. Lines of evidence have indicated that type I IFNs
play an important role in the pathogenesis of RA. Type I
IFN-related genes were significantly increased in PBMC
of RA patients [27], whereas IFN-a and IFN-b were upre-
gulated in the synovium of RA [28,29]. However, IFN-g
was lacking, or at low levels in the synovium, and rarely
detectable in the SF of patients with RA [30,31]. There-
fore, compared with above research findings, we found
that there were some similarities with respect of the
Figure 4 Cellular distribution of IL-29 in rheumatoid arthritis (RA) synovium. Double immunofluorescence analysis in RA synovium was
performed using specific antibodies against IL-29 and CD68 or FGF-2. Each section was merged with DAPI. The magnification was × 400.
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Figure 5 IL-29 induced cytokine expression by rheumatoid arthritis (RA) synovial fibroblasts. (A) Immunofluoresence staining for IL-28Ra
in MH7A cells. IL-28Ra-positive cells were stained red. The magnification was × 400. (B-E) Induction of IL-6, -8, -10 and MMP-3 in MH7A cells by
IL-29. Levels of mRNA for IL-6 (B), IL-8 (C), MMP-3 (D) and IL-10 (E) in MH7A were determined by real-time PCR after 24 h incubation with IL-29
or TNF-a (a positive control). Because the effects of IL-29 at 1 ng/ml or IL-29 incubation for 48 h on the expression of the above cytokines in
MH7A cells are similar to the medium control group or 24 h incubation, the data from IL-29 at 1 ng/ml or IL-29 incubation for 48 h in MH7A are
not shown in the figure. IL-29 could not induce the expression of IL-17 in MH7A cells and data are not shown in the figure. Relative gene
expression was determined by the 2-ΔΔct method. Values shown are the mean ± SD for five separate experiments performed in triplicate. Actual
P values are shown in the graph.
Wang et al. Arthritis Research & Therapy 2012, 14:R228
http://arthritis-research.com/content/14/5/R228
Page 8 of 10
expression and mechanism between IL-29 and type I
IFNs in the pathogenesis of RA. As a potential therapeu-
tic agent in the treatment of viral infections and cancers,
IL-29 has attracted new interest for research, because the
tissue-restricted expression of IL-29 and its receptor
make IL-29 therapy have fewer side effects than type I
IFNs therapy that is accompanied by numerous side
effects [7].
Conclusions
In summary, our data have presented new evidence that
IL-29 may contribute to synovial inflammation during
RA pathogenesis. Further studies on the induction of
IL-29 production and its underlying molecular mechan-
isms will provide a fuller understanding of a pathologi-
cal role of IL-29 in RA development.
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